Bionano (BNGO) General Counsel Dixon Receives 15,000-Share Award

What Happened

• Jonathan V. Dixon, General Counsel of Bionano Genomics (BNGO), was granted a derivative award covering 15,000 shares on Aug 3, 2026. The filing reports a $0.00 acquisition price (no cash paid). This is a grant of an option-like award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-08-03; Form filed: 2026-08-05 (this Form 4 replaces an erroneous Form 3 per the filing).
• Transaction type/code: A (Grant/award/acquisition); 15,000 derivative shares reported at $0.00.
• Vesting: Per footnote, the shares “subject to the option” vest 50% on the first anniversary and 50% on the second anniversary of the vesting commencement date, subject to continued service.
• Shares owned after transaction: Not disclosed in this filing.
• Filing note: Footnote F2 states the initial Form 3 filed Aug 5, 2026 was erroneous; this Form 4 replaces it. The filing does not indicate a late (L) timeliness flag.

Context

• This was a compensation grant (derivative/option award), not a market purchase or sale; such grants are common as retention/compensation and do not by themselves indicate insider buying or selling sentiment. If and when the options vest and are exercised, separate filings would show any exercise or sale.